Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

PEG-hirudin more effective than heparin in patients with acute coronary syndromes

Sep. 2, 1998

Canadian authorities approve use of Fragmin in treatment of heart disease

Aug. 31, 1998

BioCryst identifies development candidate in complement inhibitor program

Aug. 28, 1998

Preclinical and clinical data reported for orbofiban, a potent antiplatelet agent

Aug. 28, 1998

AR-C69931MX; a novel P2T antagonist with platelet aggregation-inhibitory activity

Aug. 28, 1998

ACS news flash: R.W. Johnson investigates thrombin inhibitors

Aug. 25, 1998

Eptifibatide treatment reduces incidence of death in acute myocardial infarction and unstable angina

Aug. 25, 1998

Corvas and Schering-Plough discontinue collaboration; other projects remain on track

Aug. 24, 1998

Novel antithrombotic agents added to the pipeline at NicOx

Aug. 17, 1998

Zeneca claims factor Xa inhibitors with antithrombotic/anticoagulant activity

Aug. 17, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...